Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press38410.17650/1994-4098-2008-0-4-64-72GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕNEW TRENDS IN THE TREATMENT OF ADVANCED OVARIAN CANCERНОВЫЕ ТЕНДЕНЦИИ В ЛЕЧЕНИИ РАСПРОСТРАНЕННОГО РАКА ЯИЧНИКОВKhohlovaS. V.ХохловаС. В.
Russian Federation
Department of chemotherapy, State Institution N.N. Blokhin Russian Cancer Research Center of Russian Academy of Medical Sciences, MoscowОтделение химиотерапии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва171120084647217092014170920142008https://ojrs.abvpress.ru/ojrs/article/view/384

Author reviews recent clinical studies of advanced ovarian cancer treatment with new chemotherapeutic agents. New schemes and modifications of available standard regimens are described, regimens with sequential administration of agents are evaluated and data concerning the use of new cytostatic agents and three-component combinations are reviewed.

НОВЫЕ ТЕНДЕНЦИИ В ЛЕЧЕНИИ РАСПРОСТРАНЕННОГО РАКА ЯИЧНИКОВ

1. Аксель Е.М., Давыдов М.И Статистика злокачественных новообразований в России и странах СНГ. М.; 2002.Аксель Е.М., Давыдов М.И Статистика злокачественных новообразований в России и странах СНГ. М.; 2002.2. Colombo N. Controversies in chemother- apy — what is standard treatment? Eur J Cancer 2003;1(6):107—14.Colombo N. Controversies in chemother- apy — what is standard treatment? Eur J Cancer 2003;1(6):107—14.3. Du Bois A., Lueck H.J., Meier W. et al. Cisplatin/paclitaxel vs carboplatin/paclitax- el in ovarian cancer. Update of an Arbeitsgemeinschaaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc ASCO 1999;18:356a.abstr 1374.Du Bois A., Lueck H.J., Meier W. et al. Cisplatin/paclitaxel vs carboplatin/paclitax- el in ovarian cancer. Update of an Arbeitsgemeinschaaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc ASCO 1999;18:356a.abstr 1374.4. Bookman M.A., McGuire W.P., Kilpatrick D. et al. Carboplatin and pacli- taxel in ovarian carcinoma. A phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895—902.Bookman M.A., McGuire W.P., Kilpatrick D. et al. Carboplatin and pacli- taxel in ovarian carcinoma. A phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895—902.5. Vasey P.A. Survival and long-term toxicity results of SCOTROC study: Docetaxel-car- boplatin v.s paclitaxel-carboplatin in epithe- lian ovarian cancer. Proc ASCO 2002;20:203a. abstr 804.Vasey P.A. Survival and long-term toxicity results of SCOTROC study: Docetaxel-car- boplatin v.s paclitaxel-carboplatin in epithe- lian ovarian cancer. Proc ASCO 2002;20:203a. abstr 804.6. Stanley B., Kaye H.D. Chemotherapy for ovarian cancer. Future potential for new and existing drugs. ASCO 2005;411—5. abstr 5136.Stanley B., Kaye H.D. Chemotherapy for ovarian cancer. Future potential for new and existing drugs. ASCO 2005;411—5. abstr 5136.7. Ozols R.F. New treatment for ovarian can- cer. Educational lectures 17th ICACT 2006.Ozols R.F. New treatment for ovarian can- cer. Educational lectures 17th ICACT 2006.8. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemothera- py versus conventional platinum-based chemotherapy in women with relapsed ovar- ian cancer, the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099—106.The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemothera- py versus conventional platinum-based chemotherapy in women with relapsed ovar- ian cancer, the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099—106.9. AGO-OVAR, NCIC CTG, EORTC GCG. Combination therapy with Gemcitabine and Carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl):36—41.AGO-OVAR, NCIC CTG, EORTC GCG. Combination therapy with Gemcitabine and Carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl):36—41.10. Salzberg M., Thurlimann B. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005;68:293—8.Salzberg M., Thurlimann B. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005;68:293—8.11. Bookman M.A. Extending the platinum- free interval in recurrent ovarian cancer: the role of topotecan in second-line chemother- apy. Oncologist 1999;4 (2):87—94.Bookman M.A. Extending the platinum- free interval in recurrent ovarian cancer: the role of topotecan in second-line chemother- apy. Oncologist 1999;4 (2):87—94.12. O'Byrne K.J., Bliss P., Graham J.D. et al. A phase 3 study of Doxil/caelyx v.s paclitaxel in platinum-treated, taxane-maive relapsed ovarian cancer. Proc ASCO 2002;21:203a. abstr 808.O'Byrne K.J., Bliss P., Graham J.D. et al. A phase 3 study of Doxil/caelyx v.s paclitaxel in platinum-treated, taxane-maive relapsed ovarian cancer. Proc ASCO 2002;21:203a. abstr 808.13. Ten Bokkel Huinink W., Gore M., Gordon A. et al. Topotecan v.s paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183—93.Ten Bokkel Huinink W., Gore M., Gordon A. et al. Topotecan v.s paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183—93.14. Урманичева А.Ф. Современная химиотерапия рака яичников. Практ он- кол 2002;3(4).Урманичева А.Ф. Современная химиотерапия рака яичников. Практ он- кол 2002;3(4).15. See H., Freedman R. et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resist- ance. Int J Gynecol Cancer 2005:15:209—16.See H., Freedman R. et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resist- ance. Int J Gynecol Cancer 2005:15:209—16.16. Crijns A., Boezen H. et al. Prognostic fac- tors in ovarian cancer: current evidence and future prospects. Eur J Cancer 2005;1:127—45.Crijns A., Boezen H. et al. Prognostic fac- tors in ovarian cancer: current evidence and future prospects. Eur J Cancer 2005;1:127—45.17. Steffensen K., Waldstrom M. et al. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Proc ASCO 2007. abstr 5568.Steffensen K., Waldstrom M. et al. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Proc ASCO 2007. abstr 5568.18. Burger R., Still M. et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peri- toneal cancer. ASCO 2005. abstr 5009.Burger R., Still M. et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peri- toneal cancer. ASCO 2005. abstr 5009.19. Cannistra S., Matulonis U. et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. ASCO 2006. abstr 5006.Cannistra S., Matulonis U. et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. ASCO 2006. abstr 5006.20. Schultheis A.M., Garcia A.A., Yang D. et al. Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophos- phamide in recurrent ovarian cancer. ASCO 2006. abstr 5017.Schultheis A.M., Garcia A.A., Yang D. et al. Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophos- phamide in recurrent ovarian cancer. ASCO 2006. abstr 5017.21. Campos S., Dizon D. et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. ASCO 2007. abstr 5517.Campos S., Dizon D. et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. ASCO 2007. abstr 5517.22. Russell J., Schilder M.D., James M. et al. Novel therapies: Update on biologic targeted strategies for ovarian cancer. Proc ASCO 2005. p. 421—7.Russell J., Schilder M.D., James M. et al. Novel therapies: Update on biologic targeted strategies for ovarian cancer. Proc ASCO 2005. p. 421—7.23. Nimeiri H.S., Faoro L. et al. Molecular correlates (EGFR status) and plasma VEGFR levels associated with a phase II study of bevacizumab plus erlotinib for patients with recurrent ovarian cancer. ASCO 2007. abstr 5554.Nimeiri H.S., Faoro L. et al. Molecular correlates (EGFR status) and plasma VEGFR levels associated with a phase II study of bevacizumab plus erlotinib for patients with recurrent ovarian cancer. ASCO 2007. abstr 5554.24. Vasey P.A., Paul J., Rustin G. et al. Maintenance erlotinib following first-line treatment with docetaxel, carboplatin and erlotinib in pts with ovarian carcinoma. ASCO 2007. abstr 5560.Vasey P.A., Paul J., Rustin G. et al. Maintenance erlotinib following first-line treatment with docetaxel, carboplatin and erlotinib in pts with ovarian carcinoma. ASCO 2007. abstr 5560.25. Pautier P., Joly F. et al. Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma. ASCO 2007. abstr 5566.Pautier P., Joly F. et al. Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma. ASCO 2007. abstr 5566.26. Schilder R., Lokshon A. Phase II trial single-agent cetuximab in patients with per- sistent or recurrent epithelial ovarian cancer or primary peritoneal carcinoma with the potential for dose escalation to rash. ASCO 2007. abstr 5577.Schilder R., Lokshon A. Phase II trial single-agent cetuximab in patients with per- sistent or recurrent epithelial ovarian cancer or primary peritoneal carcinoma with the potential for dose escalation to rash. ASCO 2007. abstr 5577.27. McMeekin D., Krasner C. et al. Final results of a phase II study of weekly tra- bectedin in second/third line ovarian cancer. ASCO 2005. abstr 5011.McMeekin D., Krasner C. et al. Final results of a phase II study of weekly tra- bectedin in second/third line ovarian cancer. ASCO 2005. abstr 5011.28. Bookman M., Darcy K. et al. Evaluation of monoclonal humanized anti-Her-2 anti- body, trastuzumab in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of Her-2. J Clin Oncol 2003;21:283—90.Bookman M., Darcy K. et al. Evaluation of monoclonal humanized anti-Her-2 anti- body, trastuzumab in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of Her-2. J Clin Oncol 2003;21:283—90.29. Guastalla J.P., Allouache D. et al. Her-2 overexpression and amplification ovarian cancer. ASCO 2007. abstr 5559.Guastalla J.P., Allouache D. et al. Her-2 overexpression and amplification ovarian cancer. ASCO 2007. abstr 5559.30. Makhija S., Glenn D. et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemc- itabine in patients with platinum-resistant ovarian, fallopian tube, or primary peri- toneal cancer. ASCO 2007. abst 5507.Makhija S., Glenn D. et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemc- itabine in patients with platinum-resistant ovarian, fallopian tube, or primary peri- toneal cancer. ASCO 2007. abst 5507.31. Vergote I., Finkler N. et al. Canfosfamide versus liposomal doxorubicin or topotecan in the third-line treatment of platinum refractory or resistant ovarian can- cer.abst. ASCO 2008. abstr LBA 5528.Vergote I., Finkler N. et al. Canfosfamide versus liposomal doxorubicin or topotecan in the third-line treatment of platinum refractory or resistant ovarian can- cer.abst. ASCO 2008. abstr LBA 5528.32. Rose P., Edwards R. et al. Canfosfamide plus carboplatin versus liposomal doxoru- bicin in the second-line treatment of plat- inum refractory or resistant ovarian cancer. ASCO 2008. abstr LBA 5529.Rose P., Edwards R. et al. Canfosfamide plus carboplatin versus liposomal doxoru- bicin in the second-line treatment of plat- inum refractory or resistant ovarian cancer. ASCO 2008. abstr LBA 5529.33. Townsley C., Hirte H., Welchs et al. Phase II of Sorafenib in combination with Gemcitabine in recurrent epithelial ovarian cancer. ECCO 2005;13;3(2). abstr 943.Townsley C., Hirte H., Welchs et al. Phase II of Sorafenib in combination with Gemcitabine in recurrent epithelial ovarian cancer. ECCO 2005;13;3(2). abstr 943.34. Verma S., Alhayki M. et al. Phase II study of exemestane in refractory ovarian cancer. ASCO 2006. abstr 5028.Verma S., Alhayki M. et al. Phase II study of exemestane in refractory ovarian cancer. ASCO 2006. abstr 5028.35. Krasner C., Debernardo R. et al. Phase II of anastrazole in combination with gefi- tinib in women with ovarian cancer. ASCO 2006. abstr 5063.Krasner C., Debernardo R. et al. Phase II of anastrazole in combination with gefi- tinib in women with ovarian cancer. ASCO 2006. abstr 5063.36. Del Campo J., Roszak A. et al. Phase II randomized open-label study of trabectedin given as two different dose schedules in women with platinum-sensitive recurrent ovarian carcinoma . ASCO 2005. abstr 5031.Del Campo J., Roszak A. et al. Phase II randomized open-label study of trabectedin given as two different dose schedules in women with platinum-sensitive recurrent ovarian carcinoma . ASCO 2005. abstr 5031.37. Hensley M., Derosa F. et al. A phase I study of pemetrexed plus gemcitabine in elapsed ovarian cancer. ASCO 2006. abstr 5083.Hensley M., Derosa F. et al. A phase I study of pemetrexed plus gemcitabine in elapsed ovarian cancer. ASCO 2006. abstr 5083.38. Smit W., Sufliarsky J. et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer. ECCO 2005;13 3(2). abstr 909.Smit W., Sufliarsky J. et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer. ECCO 2005;13 3(2). abstr 909.39. Gore M., Kaye S. et al. Phase 1 trial of patupilone plus carboplatin in patients with advanced ovarian cancer. ASCO 2006. abstr 5087.Gore M., Kaye S. et al. Phase 1 trial of patupilone plus carboplatin in patients with advanced ovarian cancer. ASCO 2006. abstr 5087.40. Rustin G., Reed N. et al. Phase II trial of Epothilone sagopilone ( ZK-EPO) in patients with platinum-resistant ovarian cancer. ASCO 2007. abstr 5527.Rustin G., Reed N. et al. Phase II trial of Epothilone sagopilone ( ZK-EPO) in patients with platinum-resistant ovarian cancer. ASCO 2007. abstr 5527.